MTNB
AMEX · Biotechnology
Matinas Biopharma Holdings I
$2.53
+0.13 (+5.42%)
Open$2.47
Previous Close$2.40
Day High$2.65
Day Low$2.34
52W High$2.02
52W Low$0.15
Volume—
Avg Volume754.4K
Market Cap2.39M
P/E Ratio—
EPS$-1.62
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+1,454.5% upside
Current
$2.53
$2.53
Target
$39.33
$39.33
$22.47
$39.33 avg
$48.65
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 545.4K | 506.2K | 440.2K |
| Net Income | -151,735 | -126,413 | -142,621 |
| Profit Margin | -27.8% | -25.0% | -32.4% |
| EBITDA | -193,711 | -167,268 | -163,365 |
| Free Cash Flow | -191,504 | -185,587 | -103,932 |
| Rev Growth | -0.1% | +13.2% | +21.4% |
| Debt/Equity | 0.35 | 0.35 | 0.32 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |